0001586494
2017-01-01
2017-12-31
0001586494
2017-12-31
0001586494
2016-12-31
0001586494
2015-12-31
0001586494
2016-01-01
2016-12-31
0001586494
2015-01-01
2015-12-31
0001586494
us-gaap:CommonStockMember
2016-01-01
2016-12-31
0001586494
us-gaap:CommonStockMember
2017-01-01
2017-12-31
0001586494
us-gaap:CommonStockMember
2015-12-31
0001586494
us-gaap:CommonStockMember
2016-12-31
0001586494
us-gaap:CommonStockMember
2017-12-31
0001586494
us-gaap:AdditionalPaidInCapitalMember
2016-01-01
2016-12-31
0001586494
us-gaap:AdditionalPaidInCapitalMember
2017-01-01
2017-12-31
0001586494
us-gaap:AdditionalPaidInCapitalMember
2015-12-31
0001586494
us-gaap:AdditionalPaidInCapitalMember
2016-12-31
0001586494
us-gaap:AdditionalPaidInCapitalMember
2017-12-31
0001586494
us-gaap:RetainedEarningsMember
2016-01-01
2016-12-31
0001586494
us-gaap:RetainedEarningsMember
2017-01-01
2017-12-31
0001586494
us-gaap:RetainedEarningsMember
2015-12-31
0001586494
us-gaap:RetainedEarningsMember
2016-12-31
0001586494
us-gaap:RetainedEarningsMember
2017-12-31
0001586494
hover:ConsultantMember
2016-01-21
0001586494
hover:ConsultantMember
2017-12-31
0001586494
hover:SeniorManagemenAndBoardOneMember
2015-12-16
2015-12-17
0001586494
2017-09-01
2017-09-02
0001586494
us-gaap:DomesticCountryMember
2017-01-01
2017-12-31
0001586494
us-gaap:StateAndLocalJurisdictionMember
2017-01-01
2017-12-31
0001586494
2018-01-01
2018-09-30
0001586494
2018-09-30
0001586494
2017-01-01
2017-09-30
0001586494
2018-07-01
2018-09-30
0001586494
2017-07-01
2017-09-30
0001586494
2017-09-30
0001586494
hover:ConsultantMember
2016-12-31
0001586494
hover:ConsultantMember
2017-11-08
0001586494
hover:ConsultantMember
2017-11-07
2017-11-08
0001586494
hover:ConsultantOneMember
2016-01-21
0001586494
hover:ConsultantOneMember
2017-12-31
0001586494
hover:ConsultantTwoMember
2017-11-08
0001586494
hover:ConsultantTwoMember
2017-11-06
2017-11-08
0001586494
hover:ConsultantTwoMember
2017-12-31
0001586494
hover:ConsultantThreeMember
2018-04-05
0001586494
hover:ConsultantThreeMember
2018-04-03
2018-04-05
0001586494
hover:ConsultantThreeMember
2017-12-31
0001586494
hover:ConsultantFourMember
2018-05-18
0001586494
hover:ConsultantFourMember
2018-05-16
2018-05-18
0001586494
hover:ConsultantFourMember
2017-12-31
0001586494
hover:ConsultantFiveMember
2018-08-28
0001586494
hover:ConsultantFiveMember
2018-08-26
2018-08-28
0001586494
hover:ConsultantFiveMember
2017-12-31
0001586494
hover:ConsultantSixMember
2018-09-21
0001586494
hover:ConsultantSixMember
2018-09-19
2018-09-21
0001586494
hover:ConsultantSixMember
2018-09-30
0001586494
hover:ConsultantOneMember
2018-09-30
0001586494
hover:ConsultantTwoMember
2018-09-30
0001586494
hover:ConsultantThreeMember
2018-09-30
0001586494
hover:ConsultantFourMember
2018-09-30
0001586494
hover:ConsultantFiveMember
2018-09-30
0001586494
hover:SeniorManagemenAndBoardMember
2018-01-01
2018-09-30
0001586494
hover:FormerVendorMember
2018-01-01
2018-09-30
0001586494
hover:ConvertibleNoteMember
2018-06-08
0001586494
hover:ConvertibleNoteMember
2018-09-30
0001586494
hover:ConsultantMember
2018-08-09
0001586494
hover:ConsultantMember
2018-08-07
2018-08-09
0001586494
hover:ThreeofficersMember
2018-08-09
0001586494
hover:ThreeofficersMember
2018-08-07
2018-08-09
0001586494
hover:SeniorManagemenAndBoardMember
2017-09-22
0001586494
hover:SeniorManagemenAndBoardMember
2017-09-21
2017-09-22
0001586494
hover:NoteHolderMember
2017-09-21
2017-09-22
0001586494
hover:NoteHolderMember
2018-01-01
2018-09-30
0001586494
hover:NoteMember
2015-12-31
0001586494
hover:NoteMember
2016-12-31
0001586494
hover:NoteMember
2017-12-31
0001586494
hover:NoteMember
2017-01-01
2017-12-31
0001586494
hover:NoteMember
2016-01-01
2016-12-31
0001586494
hover:ThreeMemberMember
2017-09-22
0001586494
hover:ThreeMemberMember
2017-09-21
2017-09-22
0001586494
hover:ThreeMemberMember
2017-11-16
2017-11-17
0001586494
hover:ThreeMemberMember
2017-11-17
0001586494
2017-09-02
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-04-05
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-04-04
2018-04-05
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-05-18
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-05-17
2018-05-18
0001586494
hover:ConvertibleNoteMember
2018-06-07
2018-06-08
0001586494
us-gaap:SubsequentEventMember
hover:ConvertibleNoteMember
2018-06-08
0001586494
us-gaap:SubsequentEventMember
hover:ConvertibleNoteMember
2018-06-07
2018-06-08
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-08-07
2018-08-09
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-08-09
0001586494
us-gaap:SubsequentEventMember
hover:ThreeofficersMember
2018-08-07
2018-08-09
0001586494
us-gaap:SubsequentEventMember
hover:ThreeofficersMember
2018-08-09
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-08-28
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-08-27
2018-08-28
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-09-21
0001586494
us-gaap:SubsequentEventMember
hover:ConsultantMember
2018-09-20
2018-09-21
0001586494
us-gaap:SubsequentEventMember
hover:FormerVendorMember
2018-09-01
2018-09-30
0001586494
hover:ConsultantSixMember
2017-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Hoverink Biotechnologies, Inc.
0001586494
S-1
2018-09-30
false
--12-31
Non-accelerated Filer
16957
7253
16957
0
7253
175
1534396
224014
2486699
147813
56133
145484
1699209
280148
2703752
6677
1387
7677
-3059059
-281555
-4333306
-1682252
-280148
-145272
1387
1387
6677
20
20
1370130
-146679
-281555
-3059059
-2696499
16957
0
7253
33024
10220
28732
6500
13103
6500
2777504
134876
1274169
1647464
608540
1001953
-1274169
-1647464
-608540
-1001953
-78
-63
-2777504
-134876
-134876
-2777504
-1274247
-1647464
-608603
-1001953
-0.12
-0.01
-0.02
-0.11
-0.01
-0.06
23962137
13872000
68713392
15050388
72470925
17331140
13872000
13872000
66772000
52900000
1000000
1000000
3000000
21900000
30000000
1000000
3000000
1375400
5290
1370110
26000
26000
234000
569400
780000
26000
234000
-1921
-35389
3879
-30191
35000
2871
35389
-4829
30191
950
-950
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – NATURE OF OPERATIONS
AND BASIS OF PRESENTATION</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an innovative preclinical biopharmaceutical
company committed to the discovery development, manufacturing and commercializing LADAVRU® and biosimilars. Our product candidate
LADAVRU® focuses on Cancer, Cirrhosis, Cirrhosis ascites, AIDS, and chronic pain, nausea and discomfort associated with chemotherapy;
our goals consist of primarily serving readily identifiable patient populations suffering from Cancer, Cirrhosis, Cirrhosis ascites,
AIDS, and chronic pain, nausea and discomfort associated with chemotherapy particularly for patients using anthracyclines with
the intention of targeting the treatment of relapsed or refractory AML. Anthracyclines are a class of chemotherapy drugs designed
to disrupt the DNA of, and eventually destroy, targeted cancer cells. They are the most effective anticancer drugs developed and
are used to treat a range of cancers, including leukemias, lymphomas, and breast, stomach, uterine, ovarian, bladder, and lung
cancers</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Corporate Information</u></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 8th, 2017, “Hoverink
Biotechnologies, Inc., a Delaware corporation, (the “Company”), with the approval of its board of directors and shareholders
owning a majority of the Company’s issued and outstanding shares by written consent in lieu of a meeting, filed a Certificate
of Change (the “ Certificate of Change:”) with the Secretary of State of Delaware.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Certificate of Change,
the Company will be changing its name to “Hoverink Biotechnologies, Inc.”, effective as of September 11, 2017.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2015, the Company implemented
a change of control by issuing shares to new shareholders, redeeming shares of existing shareholders, electing new officers and
directors and accepting the resignations of its then existing officers and directors. In connection with the change of control,
the shareholders of the Company and its board of directors unanimously approved the change of the Company’s name from Sky
Run Acquisition Corporation to Hoverink Biotechnologies, Inc. Prior to this the company was a shell as defined in Rule 405.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We were incorporated in Delaware in
July 2013 as Skyrun Acquistion Corporation. Our principal executive offices are located at 1801 Century Park E., 24th Floor Los
Angeles, California 90067.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s financial statements
are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which
contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not yet
established a stable ongoing source of revenues sufficient to covers operating costs and will continue as a going concern. The
continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability
of the Company to obtain necessary financing to sustain operations and the attainment of profitable operations. The Company had
an accumulated deficit of $3,059,059 as of December 31, 2017. These factors among others raise substantial doubt as its ability
to continue as a going concern.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to continue as a going concern,
the Company needs to develop a reliable source of revenues, and achieve a profitable level of operations. During the years ended
December 31, 2017 and December 31, 2016, the Company has been involved primarily with development of operations and applying to
trade in the public market. The Company has continued to organize and structure to meet the needs of shareholders and attract suitable
financing.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To fund operations for the next twelve
months, the Company projects a need for $5,000,000 that will have to be raised through debt or equity.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company is unable to obtain
adequate capital, it could be forced to cease operations. Accordingly, the accompanying financial statements are accounted for
as if the Company is a going concern and do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amount and classification of liabilities or other adjustments that might be necessary should the Company
be unable to continue as a going concern.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – NATURE OF OPERATIONS
AND BASIS OF PRESENTATION</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an innovative preclinical biopharmaceutical
company committed to the discovery development, manufacturing and commercializing LADAVRU® and biosimilars. Our product candidate
LADAVRU® focuses on Cancer, Cirrhosis, Cirrhosis ascites, AIDS, and chronic pain, nausea and discomfort associated with chemotherapy;
our goals consist of primarily serving readily identifiable patient populations suffering from Cancer, Cirrhosis, Cirrhosis ascites,
AIDS, and chronic pain, nausea and discomfort associated with chemotherapy particularly for patients using anthracyclines with
the intention of targeting the treatment of relapsed or refractory AML. Anthracyclines are a class of chemotherapy drugs designed
to disrupt the DNA of, and eventually destroy, targeted cancer cells. They are the most effective anticancer drugs developed and
are used to treat a range of cancers, including leukemias, lymphomas, and breast, stomach, uterine, ovarian, bladder, and lung
cancers</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>Corporate Information</u></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 8th, 2017, “Hoverink
Biotechnologies, Inc., a Delaware corporation, (the “ Company ”), with the approval of its board of directors and shareholders
owning a majority of the Company’s issued and outstanding shares by written consent in lieu of a meeting, filed a Certificate
of Change (the “ Certificate of Change ”) with the Secretary of State of Delaware.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Certificate of Change,
the Company will be changing its name to “Hoverink Biotechnologies, Inc.”, effective as of September 11, 2017.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2015, the Company implemented
a change of control by issuing shares to new shareholders, redeeming shares of existing shareholders, electing new officers and
directors and accepting the resignations of its then existing officers and directors. In connection with the change of control,
the shareholders of the Company and its board of directors unanimously approved the change of the Company’s name from Sky
Run Acquisition Corporation to Hoverink Biotechnologies, Inc. Prior to this the company was a shell as defined in Rule 405.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We were incorporated in Delaware in
July 2013 as Skyrun Acquistion Corporation. Our principal executive offices are located at 1801 Century Park E., 24th Floor Los
Angeles, California 90067.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These interim financial statements
have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which assumes that
the Company will be able to meet its obligations and continue its operations for the next fiscal year. Realizable values may be
substantially different from carrying values as shown and these condensed interim financial statements, which do not give effect
to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company
be unable to continue as a going concern. At September 30, 2018, the Company had not yet achieved profitable operations and has
an accumulated loss of $4,333,306 since inception. The Company expects to incur further losses, all of which casts substantial
doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern
is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations
and repay its liabilities arising from normal business operations when they come due. Management anticipates that additional funding
will be in the form of equity financing from the sale of common stock. Management may also seek to obtain short-term loans from
the directors of the Company. There are no current arrangements in place for equity funding or short-term loans.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and
regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions
to Form 10Q and Article of Regulation S-X. Accordingly, they do not include all the information and footnotes necessary for a comprehensive
presentation of financial position, results of operations, or cash flows. It is management’s opinion however, that all material
adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation.
The results for the interim period are not necessarily indicative of the results to be expected for the full year.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers highly liquid
financial instruments purchased with a maturity of three months or less to be cash equivalents. As of December 31, 2017, and 2017
the Company had $950, and $0, respectively of cash and cash equivalents.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we may maintain bank
balances in interest bearing accounts in excess of the $250,000 currently insured by the Federal Deposit Insurance Corporation
for interest bearing accounts (there is currently no insurance limit for deposits in noninterest bearing accounts). We have not
experienced any losses with respect to cash. Management believes our Company is not exposed to any sign of credit risk with respect
to its cash.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing financial statements in
conformity with generally accepted accounting principles in the United States of America, management makes estimates and assumptions
that affect the reported amounts of assets and liabilities in the balance sheet and revenue and expenses in the statement of operations.
The accounting estimates that require our significant, difficult, and subjective judgments include</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">the valuation and recognition of share-based compensation.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Actual results may differ from those
estimates and such differences may be material to the financial statements. The current economic environment has increased the
degree of uncertainty inherent in these estimates and assumptions.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows guidance for accounting
for fair value measurements of financial assets and financial liabilities and for fair value measurements of non financial items
that are recognized or disclosed at fair value in the financial statements on a recurring basis. Additionally, the Company adopted
guidance for fair value measurement related to non financial items that are recognized and disclosed at fair value in the financial
statements on an on recurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices inactive markets for identical
assets or liabilities (Level I measurements) and the lowest priority to measurements involving significant unobservable inputs
(Level 3 measurements). The three levels of the fair value hierarchy are as follows:</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 48px; line-height: 107%"> </td>
<td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level I inputs are quoted prices (unadjusted) inactive markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</font></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td style="text-align: justify; line-height: 107%"> </td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 inputs are inputs other than quoted prices included within Level I that are observable for the asset or liability, either directly or indirectly.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 48px; line-height: 107%"> </td>
<td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 inputs are unobservable inputs for the asset or liability.</font></td></tr>
</table>
<p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The level in the fair value hierarchy
within which a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value
measurement in its entirety.</p>
<p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advertising</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs as incurred.
During the Year ended December 31, 2017 and 2016, the Company incurred no advertising and promotion expenses. We have no existing
arrangements under which we provide or receive advertising services from others for any consideration other than cash.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Loss per Common Share</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The basic earnings (loss) per share
is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common
shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss)
available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted
average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity.
Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes the asset and liability
method of accounting for income taxes. The asset and liability method requires that the current or deferred tax consequences of
all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the
amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the
Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion
of the deferred tax assets will not be recovered.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2006, the FASB issued guidance
that clarified the accounting for income taxes by prescribing a minimum probability threshold that a tax position must meet before
a financial statement benefit is recognized. The minimum threshold is defined as a tax position that is more likely than not to
be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes,
based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that
is greater than fifty percent likely of being realized upon ultimate settlement. Company management believes that it had no material
uncertain tax positions at December 31, 2017 and 2016.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the liability method
of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax balances and tax loss carry- forwards. Deferred tax assets and liabilities are measured using enacted or substantially enacted
tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes
the date of enactment or substantive enactment.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-based Compensation</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows <font style="background-color: white">FASB
ASC 505-50, Equity – Equity-Based Payments to Non-Employees and </font>ASC 718-10, “Stock Compensation”,
which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with
a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 is
a revision to SFAS No. 123, “Accounting for Stock-Based Compensation,” and supersedes Accounting Principles Board (“APB”)
Opinion No. 25, “Accounting for Stock Issued to Employees,” and its related implementation guidance. ASC 718-10 requires
measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair
value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after
the grant date must be recognized. The Company has not adopted a stock option plan and has not granted any stock options.</p>
<p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 505-50, share-based
payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The
expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation
expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting
date.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentration of Credit Risk</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains its cash with
a major financial institution located in the United States of America which it believes to be credit worthy. Balances are insured
by the Federal Deposit Insurance Corporation up to $250,000. At times, the Company maintains balances in excess of the federally
insured limits.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks and Uncertainties</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a limited operating
history and has not generated revenue to date. The Company’s business and operations are sensitive to general business and
economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations
in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s
control could cause fluctuations in these conditions. Adverse developments in these general business and economic conditions, including
recession, downturn or otherwise, and could have a material adverse effect on the Company’s financial condition and the results
of its operations.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company will compete
with many companies that currently have extensive and well-funded projects, marketing and sales operations as well as extensive
human capital. Our company may be unable to compete successfully against these companies. The Company’s industry is characterized
by rapid changes in technology and market demands. As a result, the Company’s products, services, and/or expertise may become
obsolete and/or unmarketable. The Company’s future success will depend on its ability to adapt to technological advances,
anticipate customer and market demands, and enhance our current products and services. Further, the Company’s products and
services must remain competitive with those of other companies with substantially greater resources.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU
2016-15, <i>Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments</i>. The update
provides guidance for how certain cash receipts and cash payments are to be presented on the statement of cash flows. ASU 2016-15
will be effective for the Company beginning the first quarter of fiscal 2018. Early adoption is permitted. ASU 2016-15 is to be
adopted using the retrospective transition method, unless it is impracticable, in which case it can be applied prospectively as
of the earliest practical date. The Company does not expect the adoption of ASU 2016-15 to have a significant impact on the disclosure
or cash flow presentation in our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU 2017-09, <i>Compensation
- Stock Compensation (Topic 718): Scope of Modification Accounting</i>, which provides guidance about which changes to the terms
or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. Under the new
guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award
(as equity or liability) changes as a result of the change in terms or conditions. ASU 2017-09 will be effective for the Company
for the fiscal year ended December 31, 2019 and interim reporting periods within that year. Early adoption is permitted. The Company
expects the adoption of this guidance will not have a material effect on the Company’s financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2014-09, “Revenue from Contracts
with Customers (Topic 606).” The FASB also issued a series of other ASUs, which update ASU 2014-09 (collectively, the “new
revenue recognition standard”). This new standard replaces all previous U.S. GAAP guidance on this topic and eliminates all
industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is
recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods
or services. Company expects the impact to be immaterial on an ongoing basis.</p>
<p style="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued Accounting
Standards Update (“ASU”) 2016-02, Leases (“ASC 842”). The guidance requires lessees to recognize almost
all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained
a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model,
but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback
guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective
for fiscal years beginning after December 15, 2018. The Company is evaluating the adoption of ASC 842, but has not determined the
effects it may have on the Company’s consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has implemented all new
accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are
any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results
of operations.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim financial
statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim
financial information and with the instructions to Regulation S-X. These unaudited interim financial statements do not include
all of the information required for full annual financial statements and should be read in conjunction with the Company’s
audited financial statements for the period ended December 31, 2017, thereto contained herein this Form S-1.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the opinion of management, all adjustments
consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position;
(b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading.
The results of operations for such interim periods are not necessarily indicative of operations for a full year.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 – NOTES PAYABLE</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 21, 2016, the Company borrowed
$35,000 from a consultant. The note has no interest, and is due on demand. As of December 31, 2017 and 2016 the balance outstanding
was $35,000.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 8, 2017, the Company issued
a note of $17,000 to a consultant for the expenses the consultant had paid on behalf of the Company. The note has no interest,
and is due on November 8, 2022. As of December 31, 2017 the balance outstanding was $17,000.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 – NOTES PAYABLE</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify">On January 21, 2016, the
Company issued a note of $35,000 to a consultant for the expenses the consultant had paid on behalf of the Company. The note has
no interest, and is due on demand. As of September 30, 2018 and December 31, 2017, the balance outstanding was $35,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify">On November 8, 2017, the
Company issued a note of $17,000 to a consultant for the expenses the consultant had paid on behalf of the Company. The note has
no interest, and is due on November 8, 2022. As of September 30, 2018 and December 31, 2017, the balance outstanding was $17,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify">On April 5, 2018, the Company
issued a note of $20,069 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes has no interest,
and is due on April 5, 2022. As of September 30, 2018 and December 31, 2017, the balance outstanding was $20,069.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify">On May 18, 2018, the Company
issued a note of $15,000 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes has no interest,
and is due on May 18, 2022. As of September 30, 2018 and December 31, 2017, the balance outstanding was $15,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify">On August 28, 2018, the
Company issued a note of $16,500 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes has
no interest, and is due on August 28, 2022. As of September 30, 2018 and December 31, 2017, the balance outstanding was $16,500.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; word-spacing: 0px; text-align: justify">On September 21, 2018,
the Company issued a note of $500 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes
has no interest, and is due on September 21, 2022. As of September 30, 2018 and December 31, 2017, the balance outstanding was
$500.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 – CAPITAL STOCK</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s capitalization is
100,000,000 shares of common stock with a par value of $0.0001 per share and 20,000,000 shares of preferred stock having a par
value of $0.0001 per share. The Company had 66,772,000 and 13,872,000 shares of common stock issued and outstanding as of December
31, 2017 and 2016. The Company had no preferred stock issued and outstanding as of December 31, 2017 and 2016.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 2, 2017, the company issued
1,000,000 shares of its common stock to pay for past consulting fees. Those shares are fair valued for $0.026 per share for a total
of $26,000.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 22, 2017, the company issued
21,900,000 shares of its common stock, at par value, to pay for past consulting fees. The shares were issued to three members of
management, considered related parties. Those shares are fair valued for $0.026 per share for a total of $569,400.</p>
<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2017, the company issued
30,000,000 shares of its common stock, at par value, to pay for past consulting fees. The shares were issued to three members
of management, considered related parties. Those shares are fair valued for $0.026 per share for a total of $780,000.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 – CAPITAL STOCK</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s capitalization is
100,000,000 shares of common stock with a par value of $0.0001 per share and 20,000,000 shares of preferred stock having a par
value of $0.0001 per share. The Company had 76,772,000 and 66,772,000 shares of common stock issued and outstanding as of September
30, 2018 and December 31, 2017 and 2016. The Company had no preferred stock issued and outstanding as of September 30, 2018, and
December 31, 2017.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2018, the Company issued
1,000,000 shares of its common stock to a consultant for consulting fees. Those shares are fair valued for $0.026 per share for
a total of $26,000.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2018, the Company issued
3,000,000 shares each of its common stock to our 3 officers. Those shares are fair valued for $0.026 per share for a total of
$234,000.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 – INCOME TAXES</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our NOL will begin to expire in 2027
for federal and state purposes and could be limited for use under IRC Section 382. We have recorded a valuation allowance against
the entire net deferred tax asset balance due because we believe there exists a substantial doubt that we will be able to realize
the benefits due to our lack of a history of earnings and due to possible limitations under IRC Section 382.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We file income tax returns in the U.S.
and in the state of California with varying statutes of limitations. Our policy is to recognize interest expense and penalties
related to income tax matters as a component of our provision for income taxes. There were no accrued interest and penalties associated
with uncertain tax positions as of June 30, 2013. All operations are in California and the Company believes it has no tax positions
which could more-likely-than not be challenged by tax authorities. We have no unrecognized tax benefits and thus no interest or
penalties included in the financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net deferred tax assets consist of the
following components as of:</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td>
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2016</b></font></td>
<td style="line-height: 107%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 54%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets</font></td>
<td style="width: 1%; line-height: 107%"> </td>
<td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">642,402</font></td>
<td style="width: 1%; line-height: 107%"> </td>
<td style="width: 1%; line-height: 107%"> </td>
<td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">59,126</font></td>
<td style="width: 1%; line-height: 107%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less: valuation allowance</font></td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(642,402</font></td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(59,126</font></td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets, net</font></td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 107%"> </td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2017, the Company had
net operating loss carry forwards of approximately $3,059,059 that may be offset against future taxable income through 2027. No
tax benefit has been reported in the December 31, 2017 and 2015 consolidated financial statements since the potential tax benefit
is offset by a valuation allowance of the same amount.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that our income tax filing
positions and deductions will be sustained on audit and do not anticipate any adjustments that will result in a material change
to our financial position. Therefore, no reserves for uncertain income tax position have been recorded pursuant to ASC 740.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 7 – SUBSEQUENT EVENTS</u></b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 5, 2018, the Company issued
a note of $20,069 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes has no interest,
and is due on April 5, 2022.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 18, 2018, the Company issued
a note of $15,000 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes has no interest,
and is due on May 18, 2022.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 8, 2018, the Company issued
a convertible note of $2,500. The convertible note is unsecured, bears interest at 10% per annum and due on December 8, 2019. There
is no set conversion price as the Company does not have actively trading common shares.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2018, the Company issued
1,000,000 shares of its common stock to a consultant for consulting fees. Those shares are fair valued for $0.026 per share for
a total of $26,000.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 9, 2018, the Company issued
3,000,000 shares each of its common stock to our 3 officers. Those shares are fair valued for $0.026 per share for a total of $234,000.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 28, 2018, the Company issued
a note of $16,500 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes has no interest,
and is due on August 28, 2022.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 21, 2018, the Company issued
a note of $500 to a consultant for the expenses the consultant had paid on behalf of the Company. The notes has no interest, and
is due on September 21, 2022.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 30, 2018, the Company
was involved with litigation with a former vendor in California. The Company was served with a judgment to pay $13,228 for past
services received by the Company. The Company has accrued for these amounts as of December 31, 2017.</p>
5000000
250000
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 – NOTES PAYABLE-RELATED
PARTY</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 17, 2015, the Company borrowed
$150,000 from a member of senior management and board member. The note is due on March 31, 2019 and bears no interest and can repay
at any time without a penalty. As of December 31, 2015, the balance due under the note was $55,744. During the year ended December
31, 2016, the Company borrowed another $26,136 and repaid $25,747 under the note, the balance due was $56,133 as of December 31,
2016. During the year ended December 31, 2017, the Company borrowed another $100 and repaid $4,020 and the date due as of December
31, 2017 is $52,213.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 22, 2017, the Company issued
a note of $119,000 to a member of senior management and board member. $30,191 of the note was for cash borrowings received by the
Company and the remaining $88,809 was for expenses the note holder had paid on behalf of the Company. The note is due on September
22, 2022 and bears no interest and can repay at any time without a penalty. $23,400 was repaid against the note later in 2017 and
as of December 31, 2017 the balance due is $95,600.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31,
2018, a member of senior management and board member provided office place to the Company for no charge.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 – NOTES PAYABLE-RELATED
PARTY</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended September
30, 2018, the Company borrowed $100 and repaid $7,429 in cash from a member of senior management and board member, under the note
entered into on September 22, 2017. Also, the Company borrowed another $5,000 for expense the note holder had paid on behalf of
the Company.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 22, 2017, the Company issued
a note of $119,000 to a member of senior management and board member. $30,191 of the note was for cash borrowings received by the
Company and the remaining $88,809 was for expenses the note holder had paid on behalf of the Company. The note is due on September
22, 2022 and bears no interest and can repay at any time without a penalty.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2018 and December
31, 2017, the balance outstanding was $145,484 and $147,813, respectively.</p>
95600
35000
35000
55744
56133
52213
2027
2027
3059059
642402
59126
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and
regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions
to Form 10Q and Article of Regulation S-X. Accordingly, they do not include all the information and footnotes necessary for a
comprehensive presentation of financial position, results of operations, or cash flows. It is management’s opinion however,
that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial
statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the
full year.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim financial
statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim
financial information and with the instructions to Regulation S-X. These unaudited interim financial statements do not include
all of the information required for full annual financial statements and should be read in conjunction with the Company’s
audited financial statements for the period ended December 31, 2017, thereto contained herein this Form S-1.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the opinion of management, all adjustments
consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position;
(b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading.
The results of operations for such interim periods are not necessarily indicative of operations for a full year.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers highly liquid
financial instruments purchased with a maturity of three months or less to be cash equivalents. As of December 31, 2017, and 2017
the Company had $950, and $0, respectively of cash and cash equivalents.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we may maintain
bank balances in interest bearing accounts in excess of the $250,000 currently insured by the Federal Deposit Insurance Corporation
for interest bearing accounts (there is currently no insurance limit for deposits in noninterest bearing accounts). We have not
experienced any losses with respect to cash. Management believes our Company is not exposed to any sign of credit risk with respect
to its cash.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing financial statements in
conformity with generally accepted accounting principles in the United States of America, management makes estimates and assumptions
that affect the reported amounts of assets and liabilities in the balance sheet and revenue and expenses in the statement of operations.
The accounting estimates that require our significant, difficult, and subjective judgments include</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">the valuation and recognition of share-based compensation.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Actual results may differ from those
estimates and such differences may be material to the financial statements. The current economic environment has increased the
degree of uncertainty inherent in these estimates and assumptions.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows guidance for accounting
for fair value measurements of financial assets and financial liabilities and for fair value measurements of non financial items
that are recognized or disclosed at fair value in the financial statements on a recurring basis. Additionally, the Company adopted
guidance for fair value measurement related to non financial items that are recognized and disclosed at fair value in the financial
statements on an on recurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices inactive markets for identical
assets or liabilities (Level I measurements) and the lowest priority to measurements involving significant unobservable inputs
(Level 3 measurements). The three levels of the fair value hierarchy are as follows:</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 48px; line-height: 107%"> </td>
<td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level I inputs are quoted prices (unadjusted) inactive markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</font></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td style="text-align: justify; line-height: 107%"> </td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 inputs are inputs other than quoted prices included within Level I that are observable for the asset or liability, either directly or indirectly.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 48px; line-height: 107%"> </td>
<td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">●</font></td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 inputs are unobservable inputs for the asset or liability.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">  </p>
<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify">The level in the fair value hierarchy
within which a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value
measurement in its entirety.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Advertising</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs as incurred.
During the Year ended December 31, 2017 and 2016, the Company incurred no advertising and promotion expenses. We have no existing
arrangements under which we provide or receive advertising services from others for any consideration other than cash.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Loss per Common Share</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The basic earnings (loss) per share
is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common
shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss)
available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted
average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity.
Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes the asset and liability
method of accounting for income taxes. The asset and liability method requires that the current or deferred tax consequences of
all events recognized in the financial statements are measured by applying the provisions of enacted tax laws to determine the
amount of taxes payable or refundable currently or in future years. Deferred tax assets are reviewed for recoverability and the
Company records a valuation allowance to reduce its deferred tax assets when it is more likely than not that all or some portion
of the deferred tax assets will not be recovered.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2006, the FASB issued guidance
that clarified the accounting for income taxes by prescribing a minimum probability threshold that a tax position must meet before
a financial statement benefit is recognized. The minimum threshold is defined as a tax position that is more likely than not to
be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes,
based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that
is greater than fifty percent likely of being realized upon ultimate settlement. Company management believes that it had no material
uncertain tax positions at December 31, 2017 and 2016.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the liability method
of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax balances and tax loss carry- forwards. Deferred tax assets and liabilities are measured using enacted or substantially enacted
tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes
the date of enactment or substantive enactment.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-based Compensation</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows <font style="background-color: white">FASB
ASC 505-50, Equity – Equity-Based Payments to Non-Employees and </font>ASC 718-10, “Stock Compensation”, which
addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary
focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 is a revision
to SFAS No. 123, “Accounting for Stock-Based Compensation,” and supersedes Accounting Principles Board (“APB”)
Opinion No. 25, “Accounting for Stock Issued to Employees,” and its related implementation guidance. ASC 718-10 requires
measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair
value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after
the grant date must be recognized. The Company has not adopted a stock option plan and has not granted any stock options.</p>
<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 505-50, share-based
payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The
expense is recognized over the service period of the award. Until the measurement date is reached, the total amount of compensation
expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting
date.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentration of Credit Risk</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains its cash with
a major financial institution located in the United States of America which it believes to be credit worthy. Balances are insured
by the Federal Deposit Insurance Corporation up to $250,000. At times, the Company maintains balances in excess of the federally
insured limits.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks and Uncertainties</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a limited operating
history and has not generated revenue to date. The Company’s business and operations are sensitive to general business and
economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations
in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s
control could cause fluctuations in these conditions. Adverse developments in these general business and economic conditions, including
recession, downturn or otherwise, and could have a material adverse effect on the Company’s financial condition and the results
of its operations.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company will compete
with many companies that currently have extensive and well-funded projects, marketing and sales operations as well as extensive
human capital. Our company may be unable to compete successfully against these companies. The Company’s industry is characterized
by rapid changes in technology and market demands. As a result, the Company’s products, services, and/or expertise may become
obsolete and/or unmarketable. The Company’s future success will depend on its ability to adapt to technological advances,
anticipate customer and market demands, and enhance our current products and services. Further, the Company’s products and
services must remain competitive with those of other companies with substantially greater resources.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU
2016-15, <i>Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments</i>. The update provides
guidance for how certain cash receipts and cash payments are to be presented on the statement of cash flows. ASU 2016-15 will be
effective for the Company beginning the first quarter of fiscal 2018. Early adoption is permitted. ASU 2016-15 is to be adopted
using the retrospective transition method, unless it is impracticable, in which case it can be applied prospectively as of the
earliest practical date. The Company does not expect the adoption of ASU 2016-15 to have a significant impact on the disclosure
or cash flow presentation in our consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU 2017-09,
<i>Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</i>, which provides guidance about which changes
to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718.
Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification
of the award (as equity or liability) changes as a result of the change in terms or conditions. ASU 2017-09 will be effective for
the Company for the fiscal year ended December 31, 2019 and interim reporting periods within that year. Early adoption is permitted.
The Company expects the adoption of this guidance will not have a material effect on the Company’s financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2014-09, “Revenue from Contracts
with Customers (Topic 606).” The FASB also issued a series of other ASUs, which update ASU 2014-09 (collectively, the “new
revenue recognition standard”). This new standard replaces all previous U.S. GAAP guidance on this topic and eliminates all
industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is
recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods
or services. Company expects the impact to be immaterial on an ongoing basis.</p>
<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued Accounting
Standards Update (“ASU”) 2016-02, Leases (“ASC 842”). The guidance requires lessees to recognize almost
all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained
a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model,
but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback
guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective
for fiscal years beginning after December 15, 2018. The Company is evaluating the adoption of ASC 842, but has not determined the
effects it may have on the Company’s consolidated financial statements.</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has implemented all new
accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are
any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results
of operations.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net deferred tax assets consist of the
following components as of:</p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td>
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2016</b></font></td>
<td style="line-height: 107%"> </td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 54%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets</font></td>
<td style="width: 1%; line-height: 107%"> </td>
<td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">642,402</font></td>
<td style="width: 1%; line-height: 107%"> </td>
<td style="width: 1%; line-height: 107%"> </td>
<td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="width: 20%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">59,126</font></td>
<td style="width: 1%; line-height: 107%"> </td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less: valuation allowance</font></td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(642,402</font></td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(59,126</font></td>
<td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets, net</font></td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 107%"> </td>
<td style="line-height: 107%"> </td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
<td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
<td style="line-height: 107%"> </td></tr>
</table>
<p style="margin: 0pt"></p>
1370130
20
1629130
35000
950
hvbh
true
false
false
16007
7253
35000
35000
35000
1499396
189015
2451524
2500
17000
69069
67902
122156
32937
61886
17937
51375
1301178
2500
952500
983678
317500
348678
1375400
260000
595400
260000
595400
-2777504
-134876
-1274247
-1647464
-608603
-1001953
1416190
99487
1009197
1052064
30291
26136
150000
100
30191
100
30191
100
26136
2500
27420
25747
7429
7429
88809
5000
4020
25747
17000
52069
88809
5000
88809
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 – CONVERTIBLE NOTE</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 8, 2018, the Company issued
a convertible note of $2,500. The convertible note is unsecured, bears interest at 10% per annum and due on December 8, 2019.
As of September 30, 2018, the balance outstanding was $2,500. There is no set conversion price as the Company does not have actively
trading common shares.</p>
<p style="margin: 0pt"></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 – COMMITMENTS AND CONTENGENCIES</b></p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 30, 2018, the Company
was involved with litigation with a former vendor in California. The Company was served with a judgment to pay $13,228 for past
services received by the Company. The Company has accrued for these amounts as of September 30, 2018.</p>
17000
35000
17000
20069
15000
16500
500
2500
119000
20069
15000
2500
16500
500
2019-03-31
2022-11-08
2022-11-08
2022-04-05
2022-05-18
2022-08-28
2022-09-21
2022-09-22
2022-04-05
2022-05-18
2019-12-08
2019-12-08
2022-08-28
2022-09-21
17000
35000
17000
20069
15000
16500
500
35000
17000
20069
15000
16500
500
13228
13228
2500
0.10
0.00
0.00
0.10
0.00
0.00
0.026
0.026
0.026
0.026
0.026
0.026
0.026
23400
66772000
13872000
76772000
66772000
13872000
76772000
100000000
100000000
100000000
0.0001
0.0001
0.0001
20000000
20000000
20000000
0.0001
0.0001
0.0001
642402
59126
78
63
175
16007
-8754
30191